Epidemiology

You have full text access to this OnlineOpen article

POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: Design, methods and baseline data of 44,102 women

  1. Nicole W.J. Bulkmans1,
  2. Lawrence Rozendaal1,
  3. Peter J.F. Snijders1,
  4. Feja J. Voorhorst2,
  5. A. Joan P. Boeke3,
  6. Gladys R.J. Zandwijken1,
  7. Folkert J. van Kemenade1,
  8. René H.M. Verheijen4,
  9. Krijn v Groningen5,
  10. Mathilde E. Boon6,
  11. Hans J.F. Keuning7,
  12. Marjolein van Ballegooijen8,
  13. Adriaan J.C. van den Brule1,
  14. Chris J.L.M. Meijer1,†,*

Article first published online: 9 FEB 2004

DOI: 10.1002/ijc.20076

Issue

International Journal of Cancer

International Journal of Cancer

Volume 110, Issue 1, pages 94–101, 20 May 2004

Additional Information

How to Cite

Bulkmans, N. W.J., Rozendaal, L., Snijders, P. J.F., Voorhorst, F. J., Boeke, A. J. P., Zandwijken, G. R.J., van Kemenade, F. J., Verheijen, R. H.M., v Groningen, K., Boon, M. E., Keuning, H. J.F., van Ballegooijen, M., van den Brule, A. J.C. and Meijer, C. J.L.M. (2004), POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: Design, methods and baseline data of 44,102 women. Int. J. Cancer, 110: 94–101. doi: 10.1002/ijc.20076

Author Information

  1. 1

    Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands

  2. 2

    Department of Clinical Epidemiology and Bio-statistics, VU University Medical Center, Amsterdam, The Netherlands

  3. 3

    Institute for Research in Extramural Medicine, VU University Medical Center, Amsterdam, The Netherlands

  4. 4

    Department of Obstetrics and Gynaecology, VU University Medical Center, Amsterdam, The Netherlands

  5. 5

    Spaarne Ziekenhuis, Heemstede, The Netherlands

  6. 6

    Leiden Cytology and Pathology Laboratory, Leiden, The Netherlands

  7. 7

    Stichting PA Laboratorium Kennemerland, Haarlem, The Netherlands

  8. 8

    Department of Public Health and Social Medicine, Erasmus Medical Center, The Netherlands

  1. †

    Fax: +31-20-4442964

*Department of Pathology, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands

Publication History

  1. Issue published online: 25 MAR 2004
  2. Article first published online: 9 FEB 2004
  3. Manuscript Accepted: 7 OCT 2003
  4. Manuscript Revised: 11 AUG 2003
  5. Manuscript Received: 18 MAR 2003

Funded by

  • ZON. Grant Number: 30-05220

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (253K)

REFERENCES

  • 1
    Sigurdsson K. Effect of organized screening on the risk of cervical cancer. Evaluation of screening activity in Iceland, 1964–1991. Int J Cancer 1993; 54: 563–70.
    Direct Link:
  • 2
    Vizcaino AP, Moreno V, Bosch FX, Munoz N, Barros-Dios XM, Borras J, Parkin DM. International trends in incidence of cervical cancer: II. Squamous-cell carcinoma. Int J Cancer 2000; 86: 429–35.
    Direct Link:
  • 3
    Vizcaino AP, Moreno V, Bosch FX, Munoz N, Barros-Dios XM, Parkin DM. International trends in the incidence of cervical cancer: I. Adenocarcinoma and adenosquamous cell carcinomas. Int J Cancer 1998; 75: 536–45.
    Direct Link:
  • 4
    Bergstrom R, Sparen P, Adami HO. Trends in cancer of the cervix uteri in Sweden following cytological screening. Br J Cancer 1999; 81: 159–66.
  • 5
    Nanda K, McCrory DC, Myers ER, Bastian LA, Hasselblad V, Hickey JD, Matchar DB. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 2000; 132: 810–9.
  • 6
    Fahey MT, Irwig L, Macaskill P. Meta-analysis of Pap test accuracy. Am J Epidemiol 1995; 141: 680–9.
  • 7
    van Ballegooijen M, van den Akker-van Marle ME, Patnick J, Lynge E, Arbyn M, Anttila A, Ronco G, Habbema DJ. Overview of important cervical cancer screening process values in European Union (EU) countries, and tentative predictions of the corresponding effectiveness and cost-effectiveness. Eur J Cancer 2000; 36: 2177–88.
  • 8
    Clavel C, Masure M, Bory JP, Putaud I, Mangeonjean C, Lorenzato M, Nazeyrollas P, Gabriel R, Quereux C, Birembaut P. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer 2001; 84: 1616–23.
  • 9
    Zielinski GD, Snijders PJ, Rozendaal L, Voorhorst FJ, Runsink AP, de Schipper FA, Meijer CJ. High-risk HPV testing in women with borderline and mild dyskaryosis: long-term follow-up data and clinical relevance. J Pathol 2001; 195: 300–6.
    Direct Link:
  • 10
    Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12–9.
    Direct Link:
  • 11
    Remmink AJ, Walboomers JM, Helmerhorst TJ, Voorhorst FJ, Rozendaal L, Risse EK, Meijer CJ, Kenemans P. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. Int J Cancer 1995; 61: 306–11.
    Direct Link:
  • 12
    Franco EL, Duarte-Franco E, Ferenczy A. Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection. CMAJ 2001; 164: 1017–25.
  • 13
    Ho GY, Burk RD, Klein S, Kadish AS, Chang CJ, Palan P, Basu J, Tachezy R, Lewis R, Romney S. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995; 87: 1365–71.
  • 14
    Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55: 244–65.
  • 15
    Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, Rozendaal L, Remmink AJ, Risse EK, van der Linden HC, Voorhorst FJ, Kenemans P, Meijer CJ. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 1999; 354: 20–5.
  • 16
    Nobbenhuis MA, Helmerhorst TJ, van den Brule AJ, Rozendaal L, Voorhorst FJ, Bezemer PD, Verheijen RH, Meijer CJ. Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear. Lancet 2001; 358: 1782–3.
  • 17
    Manos MM, Kinney WK, Hurley LB, Sherman ME, Shieh-Ngai J, Kurman RJ, Ransley JE, Fetterman BJ, Hartinger JS, McIntosh KM, Pawlick GF, Hiatt RA. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA 1999; 281: 1605–10.
  • 18
    Rozendaal L, Westerga J, van der Linden JC, Walboomers JM, Voorhorst FJ, Risse EK, Boon ME, Meijer CJ. PCR based high risk HPV testing is superior to neural network based screening for predicting incident CIN III in women with normal cytology and borderline changes. J Clin Pathol 2000; 53: 606–11.
  • 19
    Kulasingam SL, Hughes JP, Kiviat NB, Mao C, Weiss NS, Kuypers JM, Koutsky LA. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA 2002; 288: 1749–57.
  • 20
    Cuzick J, Beverley E, Ho L, Terry G, Sapper H, Mielzynska I, Lorinez A, Chan WK, Krausz T, Soutter P. HPV testing in primary screening of older women. Br J Cancer 1999; 81: 554–8.
  • 21
    Schiffman M, Adrianza ME. ASCUS-LSIL Triage Study. Design, methods and characteristics of trial participants. Acta Cytol 2000; 44: 726–42.
  • 22
    Ratnam S, Franco EL, Ferenczy A. Human papillomavirus testing for primary screening of cervical cancer precursors. Cancer Epidemiol Biomarkers Prev 2000; 9: 945–51.
  • 23
    Sherman ME, Lorincz AT, Scott DR, Wacholder S, Castle PE, Glass AG, Mielzynska-Lohnas I, Rush BB, Schiffman M. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst 2003; 95: 46–52.
  • 24
    Schneider A, Hoyer H, Lotz B, Leistritza S, Kuhne-Heid R, Nindl I, Muller B, Haerting J, Durst M. Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy. Int J Cancer 2000; 89: 529–34.
    Direct Link:
  • 25
    Petry KU, Menton S, Menton M, Loenen-Frosch F, de Carvalho GH, Holz B, Schopp B, Garbrecht-Buettner S, Davies P, Boehmer G, van den Akker E, Iftner T. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. Br J Cancer 2003; 88: 1570–7.
  • 26
    Lorincz AT, Richart RM. Human papillomavirus DNA testing as an adjunct to cytology in cervical screening programs. Arch Pathol Lab Med 2003; 127: 959–68.
  • 27
    van Ballegooijen M, Hermens R. Cervical cancer screening in the Netherlands. Eur J Cancer 2000; 36: 2244–6.
  • 28
    Hanselaar AG. Criteria for organized cervical screening programs. Special emphasis on The Netherlands program. Acta Cytol 2002; 46: 619–29.
  • 29
    Jacobs MV, Snijders PJ, van den Brule AJ, Helmerhorst TJ, Meijer CJ, Walboomers JM. A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol 1997; 35: 791–5.
  • 30
    Schiffman M, Herrero R, Hildesheim A, Sherman ME, Bratti M, Wacholder S, Alfaro M, Hutchinson M, Morales J, Greenberg MD, Lorinez AT. HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica [see comments]. JAMA 2000; 283: 87–93.
  • 31
    Bos AB, van Ballegooijen M, van den Akker-van Marle ME, Habbema JD. [ Less pap-2 results (‘minor abnormalities’) in the population screening for cervical cancer since the introduction of new guidelines in 1996]. Ned Tijdschr Geneeskd 2002; 146: 1586–90.
  • 32
    Wright TC Jr, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ. 2001 Consensus guidelines for the management of women with cervical cytological abnormalities. JAMA 2002; 287: 2120–9.
  • 33
    Bulk S, van Kamenade FJ, Rozendaal L, Meijer CJLM. The Dutch CISOE-A framework for cytology reporting increases efficacy of screening upon standardization since 1996. J Clin Pathol 2004; in press.
View Full Article (HTML) Get PDF (253K)